MHRA paediatric investigation plan
VidPrevtyn Beta (Recombinant SARS-CoV-2 spike protein)
MHRA paediatric investigation plan MHRA-100038-PIP01-21-M03 (update) · Waiver
Key facts
| PIP number | MHRA-100038-PIP01-21-M03 (update) |
|---|---|
| Product names | VidPrevtyn Beta |
| Active substances | Recombinant SARS-CoV-2 spike protein |
| Therapeutic areas | Vaccines |
| Conditions | Prevention of coronavirus disease 2019 (COVID-19) |
| Decision | W: decision granting a waiver in all age groups for the listed condition(s). |
| Published | Aug 15, 2024 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: